دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Embarrassment of Riches: Combining SGLT2 Inhibitors and Nonsteroidal Mineralocorticoid Antagonists for the Treatment of Diabetic Kidney Disease
Haller H.a,b
doi : 10.1159/000516214
Am J Nephrol 2021;52:605–607
Risk Stratification prior to Cardiac Surgery: Another Important Lesson Learned
Jefferies J.L.
doi : 10.1159/000518241
Am J Nephrol 2021;52:608–610
Denosumab-Induced Hypocalcemia and Hyperparathyroidism in de novo Kidney Transplant Recipients
Cianciolo G.a · Tondolo F.a · Barbuto S.a · Iacovella F.a · Zavatta G.b · Altieri P.b · Grandinetti V.a · Comai G.a · Cozzolino M.c · La Manna G.a
doi : 10.1159/000518363
Am J Nephrol 2021;52:611–619
Denosumab represents a realistic treatment option to increase bone mineral density in kidney transplant recipients (KTRs). It is still unknown how and at what extent posttransplantation bone disease and graft function influence the effects of denosumab on mineral metabolism indexes. In this study, we analyze risk factors of hypocalcemia and parathyroid hormone (PTH) increase after denosumab administration in eighteen de novo KTRs and its management before and after this treatment.
Synbindin Downregulation Participates in Slit Diaphragm Dysfunction
Ivanov V. · Fukusumi Y. · Zhang Y. · Yasuda H. · Kitazawa M. · Kawachi H.
doi : 10.1159/000517975
Am J Nephrol 2021;52:620–629
Synbindin, originally identified as a neuronal cytoplasmic molecule, was found in glomeruli. The cDNA subtractive hybridization technique showed the mRNA expression of synbindin in glomeruli was downregulated in puromycin aminonucleoside (PAN) nephropathy, a mimic of minimal-change nephrotic syndrome.
Predicting Future Renal Function Decline in Patients with Autosomal Dominant Polycystic Kidney Disease Using Mayo Clinic Classification
Borrego Utiel F.J.a · Esteban de la Rosa R.J.b · Merino García E.a · Medina Benítez A.c · Polo Moyano A.b · Moriana Domínguez C.a · Morales García A.I.b · Bravo Soto J.A.b
doi : 10.1159/000518255
Am J Nephrol 2021;52:630–641
Mayo clinic classification (MCC) has been proposed in patients with autosomal dominant polycystic kidney disease (ADPKD) to identify who may experience a rapid decline of renal function. Our aim was to validate this predictive model in a population from southern Spain.
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
Kolkhof P.a · Hartmann E.b · Freyberger A.c · Pavkovic M.d · Mathar I.a · Sandner P.a · Droebner K.a · Joseph A.e · Hüser J.a · Eitner F.a
doi : 10.1159/000516213
Am J Nephrol 2021;52:642–652
The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated clinical benefits in CKD patients with type 2 diabetes. Clinical data analyzing the potential value of a combination therapy are currently limited. We therefore investigated cardiorenal protection of respective mono- and combination therapy in a preclinical model of hypertension-induced end-organ damage.
Transforming Growth Factor-?1/Smad Signaling in Glomerulonephritis and Its Association with Progression to Chronic Kidney Disease
Chalkia A.a · Gakiopoulou H.b · Theohari I.b · Foukas P.G.c · Vassilopoulos D.d · Petras D.a
doi : 10.1159/000517619
Am J Nephrol 2021;52:653–665
Transforming growth factor-?1 (TGF-?1) is a multifunctional cytokine, with diverse roles in fibrosis and inflammation, which acts through Smad signaling in renal pathology. We intended to investigate the expression of TGF-?/Smad signaling in glomerulonephritis (GN) and to assess its role as risk factor for progression to chronic kidney disease (CKD).
Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease
Ciardullo S.a,b · Ballabeni C.c · Trevisan R.b,d · Perseghin G.a,b
doi : 10.1159/000518111
Am J Nephrol 2021;52:666–672
Obese (OB) patients are at increased risk of chronic kidney disease, but it is still unclear whether this can be attributed to obesity per se or to the associated metabolic derangements. The aim of this study was to evaluate the relative impact of obesity and metabolic syndrome (MS) on kidney disease.
Urine Alpha-1-Microglobulin Levels and Acute Kidney Injury, Mortality, and Cardiovascular Events following Cardiac Surgery
Amatruda J.G.a,b · Estrella M.M.a,b,c · Garg A.X.d,e · Thiessen-Philbrook H.f · McArthur E.e · Coca S.G.g · Parikh C.R.f · Shlipak M.G.b,h · for the TRIBE-AKI Consortium
doi : 10.1159/000518240
Am J Nephrol 2021;52:673–683
Urine alpha-1-microglobulin (U?1m) elevations signal proximal tubule dysfunction. In ambulatory settings, higher U?1m is associated with acute kidney injury (AKI), progressive chronic kidney disease (CKD), cardiovascular (CV) events, and mortality. We investigated the associations of pre- and postoperative U?1m concentrations with adverse outcomes after cardiac surgery.
Preimplantation Genetic Testing for Kidney Disease-Related Genes: A Laboratory’s Experience
Chaperon J.L.a · Wemmer N.M.a · McKanna T.A.a · Clark D.M.a · Westemeyer M.A.a · Gauthier P.a · Bai Y.a · Coleman J.M.b
doi : 10.1159/000518253
Am J Nephrol 2021;52:684–690
Recent literature highlights the clinical utility of genetic testing for patients with kidney disease. Genetic testing provides significant benefits for reproductive risk counseling, including the option of in vitro fertilization with preimplantation genetic testing for monogenic disease (PGT-M). PGT-M allows for a significant reduction in risk for a pregnancy affected with the familial disease. We aim to summarize our experience with PGT-M for genes with kidney involvement as either a primary or secondary feature of the disease.
Induction Therapy, HLA Mismatching, and Standard-Risk Kidney Transplantation
Nassar M.a · Elshafey M.b · Gonzalez C.a · Nso N.a · Mahdi M.c · Elsayed I.d
doi : 10.1159/000517908
Am J Nephrol 2021;52:691
